Pharmaceutical Bulk Fluvoxamine maleate Powder

CAS:61718-82-9

MF: C19H25F3N2O6

MW: 434.41

EINECS: 612-212-6

Specification​: 99% min Fluvoxamine maleate Powder

Sample: Fluvoxamine maleate Powder

Packaging:1kg/bag, 25kg/drum

Brand: Henrikang

Appearance: White Powder

Storage: Cool Dry Place

Shelf Life: 2 Years

Test Method: HPLC

Fluvoxamine maleate Powder Usage and Synthesis.

1, This product should not be combined with monoamine oxidase inhibitors.

2、No synergistic reactions have been observed between this product and digoxin and atenolol.

3, As with other psychiatric medications, alcohol intake should be avoided during the administration of fluvoxamine maleate.

4, This product may slow down the breakdown of drugs metabolised by the liver. When combined with warfarin, phenytoin, theophylline and carbamazepine, it produces significant clinical effects. If used in combination, please adjust the dose of these drugs.

5. Fluvoxamine maleate may increase the plasma concentration of oxidatively metabolised benzodiazepines. It has been reported that fluvoxamine maleate may increase the original steady-state plasma concentration of tricyclic antidepressants, and it is recommended that this product not be used concomitantly with tricyclic antidepressants.

6, this product can increase the plasma level of cardiac glycosides, it is recommended to reduce the dose of cardiac glycosides when taken together.

7, this product and warfarin co-administration for a fortnight, warfarin plasma concentration increased significantly and prolonged clotting time. Patients taking oral anticoagulants and fluvoxamine should monitor the clotting time and adjust the dose of fluvoxamine accordingly.

8, the treatment of severe, already drug-resistant depressed patients, this product can be combined with lithium. However, lithium and tryptophan may exacerbate the 5-hydroxytryptaminergic effects of fluvoxamine.

Uses and functions of Fluvoxamine maleate.

Fluvoxamine Maleate is a film-coated tablet that appears white or off-white when the coating is removed. It is used effectively in the treatment of depression and major depressive disorders by regulating serotonin concentrations through 5HT4-receptor antagonism and inhibition of selective serotonin reuptake.

Fluvoxamine Maleate is used in the treatment of depression and related symptoms, obsessive-compulsive disorder symptoms treatment.

Pharmacological Effects of Fluvoxamine maleate Raw Materials.

Fluvoxamine maleate is the only selective 5-hydroxytryptamine (5-HT) reuptake inhibitor (SSRI) with a monocyclic structure, which exerts antidepressant effects by selectively inhibiting the reuptake of 5-HT in the presynaptic membranes of the CNS, and increasing the effective concentration of 5-HT in the synaptic gap.

Fluvoxamine maleate blocks 5-HT reuptake more strongly than fluoxetine, amitriptyline, promethazine, and desipramine, but is weaker than paroxetine, sertraline, and propitalopram.

Fluvoxamine maleate has little or no effect on the uptake of dopamine and norepinephrine, and has no affinity for alpha and beta-adrenergic, M-cholinergic, and histamine H1 receptors, and thus has none of the adverse effects that result from binding to these receptors, such as dry mouth, constipation, sedation, extrapyramidal disorders, and orthostatic hypotension.

Production method of Fluvoxamine maleate Raw Powder.

Fluvoxaminemaleate also exhibited anti-injury perception in a dose-dependent manner in a paw stress test in non-ligated mice.Fluvoxaminemaleate also induced anti-injury effects in an acute paw stress test and this effect was antagonised by the 5-HT3 receptor antagonist, granisetron. In rat hippocampal medial prefrontal cortex (mPFC), Fluvoxamine (10 and 30 mg/kg, intraperitoneally) enhanced hippocampal-mPFC pathway synaptic efficacy in a dose-dependent manner. In the hippocampal CA1 region of anaesthetised rats, Fluvoxamine (10 and 30 mg/kg, intraperitoneal injection) inhibited long-time potentiation (LTP).

Fluvoxamine (30 mg/kg Chemicalbook, intraperitoneal injection) induced LTP that was completely reversed by the 5-HT(1A) receptor antagonist NAN-190 (0.5 mg/kg, intraperitoneal injection), but not by the 5-HT(4) receptor antagonist GR113808 (20 mg/rat, intraventricular injection), as well as the 5-HT ( (7) receptor antagonist DR4004 (10 mg/rat, ventricular injection).Fluvoxaminemaleate potentiated the response to norepinephrine in rat vas deferens incubated in Krebs-Henseleit solution isolates.

Fluvoxaminemaleate and Fluxetine hydrochloride inhibited the induction of contraction of isolated rat uterine preparations by potassium ions with IC50s of 3.99 μM and 18.2 μM, respectively.